Welcome To Our Site!

Research & Development
The company boasts a research team of over 200 master's and doctoral-level experts specializing in chemical synthesis, separation and purification, quality research, and biotechnology, supported by state-of-the-art R&D equipment including 600M and 400M NMR spectrometers, multiple Orbitrap Fusion, Q Exactive, and Triple TOF high-resolution mass spectrometers—totaling over 100 million yuan in advanced instrumentation. Leveraging a multidisciplinary technical platform, the company has built an integrated, cross-disciplinary R&D system with core competencies in challenging compound synthesis, separation and purification, and quality research.

Production Facilities
The company operates a 50-acre GMP-compliant synthetic manufacturing facility equipped with reactors ranging from 200L to 10,000L, capable of handling demanding chemical reactions such as high-temperature, hydrogenation, and high-pressure processes. This enables seamless transition from laboratory-scale development to large-scale production, ensuring consistent product supply and service quality.

Core Products & Services

GLP-1 Peptide Drug Intermediates
Key products include fatty acid side chains and short peptide fragments. Core products achieve single impurity levels below 0.10% and batch capacities exceeding 300 kg, supported by comprehensive quality research to fully meet regulatory submission requirements. Currently, Changsha Chenchen serves as a global key supplier for fatty acid side chains used in GLP-1 drugs such as semaglutide and tirzepatide.

Monodisperse PEG Derivatives
Utilizing proprietary synthesis and purification technologies, the company maintains extremely low levels of homologous impurities (e.g., <0.10%, <0.15%, and <0.3% for PEG8, PEG12, and PEG24 homologues, respectively), while supporting customized functional group modifications to precisely meet diverse drug requirements.

Nucleic Acid Drug Intermediates
The company provides high-quality cap analogs, GalNAc, linkers, and other intermediates, with GalNAc achieving purity above 99.5% and single impurity levels below 0.10%.

CRO/CDMO Services
Comprehensive coverage across small-molecule and biotechnology domains, particularly in full-process pharmaceutical development, post-approval supplement studies, impurity profiling, genotoxic impurity analysis, and pharmaceutical development for biologics such as antibodies, ADCs, peptides, and nucleic acids, as well as proteomics research. With leading technological capabilities, the company sets industry benchmarks in these fields. Collapse

Certificate